a place fir glp.1 and eating disprders 504: Adult Disorders in the GLP-1 Era Harm Reduction for Eating Disorders

Three pilot studies with very small sample sizes, a Phase II trial whose results remain unpublished, and a regulatory record that reflects the FDA's own assessment that sufficient human safety data do not exist that is the complete ledger as of 2025

Because it increases ROS production and lowers antioxidant levels, excessive iodine consumption is considered an additional risk factor for developing AITD

Treatments Resources Who We Are Work With Us Treatments Resources Who We Are Work With Us Treatments Resources Who We Are Work With Us Treatments Resources Who We Are Work With Us All articles Do GLP-1 Agonists Cause Gallstones

Endocrinology 119 (2), 940942

(2025, August 9)